Apogee Therapeutics, Inc. APGE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $229.14M+23.5% | $214.71M+27.9% | $216.5M+58.5% | $208.03M+92.7% | $185.54M+109% | ||
| $76.13M+35.3% | $70.88M+44.6% | $66.92M+61.1% | $62.8M+75.3% | $56.25M+88.5% | ||
| $305.27M+26.3% | $285.6M+31.7% | $283.42M+59.1% | $270.83M+88.4% | $241.79M+104% | ||
| -$305.27M-26.3% | -$285.6M-31.7% | -$283.42M-59.1% | -$270.83M-88.4% | -$241.79M-104% | ||
| $30.93M-15.2% | $30.03M-13.6% | $29.98M-4.8% | $33.33M+31.9% | $36.5M+144% | ||
| -$274.34M-33.6% | -$255.57M-40.3% | -$253.44M-86.5% | -$237.5M-120% | -$205.29M-116% | ||
| $274K+171% | $278K+1,444% | $234K— | $173K— | $101K— | ||
| -$274.62M-33.7% | -$255.84M-40.5% | -$253.67M-73.0% | -$237.67M-101% | -$205.39M-98.3% | ||
| -$4.33-20.3% | -$4.22-28.3% | -$4.38-81.0% | -$4.13-99.5% | -$3.60+31.4% | ||
| -$303.66M-25.8% | -$284.18M-31.2% | -$282.34M— | -$270.1M— | -$241.42M— | ||
| -$305.27M-26.3% | -$285.6M-31.7% | -$283.42M-59.1% | -$270.83M-88.4% | -$241.79M-104% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Apogee Therapeutics, Inc. profitable?
- Apogee Therapeutics, Inc. is not currently profitable: it reported a net loss of $274.6M over the trailing twelve months.
- What is Apogee Therapeutics, Inc.'s earnings per share?
- Apogee Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does Apogee Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.